Eden Research Share Discussion Threads

[woolybanana] 23/5/2017 15:05

Thank you everyone.

[sweet karolina] 23/5/2017 11:29

Woolybanana. The reason for the fraud was simple. Eden was out of cash so they committed fraud to raise it. It really is that simple.

You are right that the damage done to the credibility of the company outweighs any short term advantage committing fraud as opposed to raising the money in a discounted placing would have caused. Eden can keep spinning its lies about Terpenetech, but as each set of results come out there will be further hits to profits and NAV. All the waffle about the drop in revenue being down to a change in focus is easily seen through. FRC forced them to restate their accounts. It would probably have been better to accept the hit in one go and restate revenue as well rather than try to bluster, but as supersonico shows once you start lying it becomes impossible to stop.

[sweet karolina] 23/5/2017 11:13

Another lie from the proven liar.

[supersonico] 23/5/2017 10:59

Could be because the technology has been validated by multiple huge multinationals, Eastman SumiAgro/ Bayer/ Sipcam ..plus the intellectual property is novel and therefore valuable.

[woolybanana] 23/5/2017 10:52

Might I just add a drop of interest and 'real' fact to this tedious and rather desperate debate, regrettably a drop of cold water? This year there were late frosts in some of the grape growing areas in France, Le Bordelaise being one, which means that the grape harvest will be severely damaged (over 50% down in some areas). This probably means that there will be reduced demand for Mevalone and any other treatments, unfortunately.

Secondly, it is surprising that no one has asked why the Terpentech fraud (if it was so) took place as there seems to have been little advantage to the company. Perhaps of of you clever and rather mouthy posters could enlighten me.

[birotop] 23/5/2017 10:49

Numpty - why don't you ask them.....

[quazie12] 23/5/2017 08:47

Really Northwick ?SS has been on here for years spouting total pish largely about TW yet cannot answer simple questions when challenged eg re Terpenetech which was a total shareholder shaft and was the sole reason I baled from this POS. Why do you want SK to clear off exactly ? So you have a nice little ramper group on here ?

[pj 1] 23/5/2017 08:03

Northwick-I'd normally say Id look forward to seeing your figures, but sadly the news last night has put lots into perspective....

[birotop] 23/5/2017 07:55

Busy day for the Brady Bunch.....

[sweet karolina] 23/5/2017 07:54

So no apology from the PROVEN LIAR supersonico for all her lying posts. No surprise.

How many days is it since FRC last contacted Eden?

[redhill9] 23/5/2017 07:44

Also 3AEY is being marketed strongly in France and elsewhere by SumiAgro who are a major player.

[supersonico] 22/5/2017 23:03

Pugugly

The French grower in this program contacted the BBC independently of Eden.. if he/she is doing that imagine what he/she is telling other growers locally and at meetings etc.

Listen from 23 mins



Mevalone/Nirka/Yatta #SEIPRO...Promotion

[pugugly] 22/5/2017 22:54

NORTHWICK:> you may well be right but what does not seem to have been factored in is that the French wine grower is very very very conservative and is unlikely to switch treatments without a lot of hard evidence from other growers he trusts (i.e. neighbours in his region) rather than field reseach from a bloody firm in Angleterre.

[supersonico] 22/5/2017 22:50

There can be no comparison with previous years now Eden have approvals and products beginning to be sold on a global basis..
With the business coming down the pipe and the high barrier to entry I would anticipate 40% annual increase in sales to be extremely conservative.

Time will tell. all IMO

SHORE CAPITAL

EDEN RESEARCH+ (EDEN, House stock at 12p) Preliminary results. Eden Research (‘Eden’) has issued preliminary results for its year ended December 2016. The results follow on from the trading update issued in December 2016 in which some financial guidance was provided. The results confirm revenue for the year of £0.4m with an adjusted operating loss of £1.1m (FY2015A: £0.2m). When including amortisation and share based payment costs the operating loss increases on a reported basis to £1.9m (FY2015A: £1.1m). The reported loss before tax is also £1.9m (FY2015A: £1.3m) which equates to a loss per share of 1.03p compared to 0.74p in the prior year. The company finished the year with a slightly higher net cash position than previously indicated (+£0.1m) at £1.5m (FY2015A: 0.2m). The cash position has benefited from the £2.6m capital raising in March 2016.
Operationally, there has been progress during the year with the first commercial sales of 3AEY in Italy (where it is sold as 3logy®), Greece (Mevalone™), Kenya (Hawk™) and Spain (ARAW®). Post the period end 3AEY also had approval granted in France and Eden has received its first commercial scale order for the product in France from SumiAgro. An exclusive commercialisation agreement with Eastman Chemical has also been signed for the company’s nematicide product B2Y and there the agreement covers 29 countries including the largest markets for nematicide products globally.
Looking ahead the company highlight its expects significant increase in product distribution in FY2017F driven by 3AEY sales in France, Spain and Italy helping drive a significant increase in revenue from that of previous years. Management also highlight there has been strong interest from distributors looking to sell 3AEY in a number of territories outside the EU and it expects to conclude arrangements to broaden distribution on this basis within the next twelve months. R&D work continues at pace and management also state it is investing further this year in regulatory approvals to enable the group’s products being sold on a more global basis.
We continue to believe Eden is well-placed with a growing and diverse product development pipeline in an industry that is seeing structural growth in demand for natural solutions. This is in the context of it getting harder to get product registrations for synthetic conventional pesticides which is a market with an overall value of over $57bn per year. So with higher barriers to entry we believe Eden is well-placed to drive value creation going forward. House Stock.
+Shore Capital Stockbrokers Limited acts as broker and Shore Capital & Corporate Limited acts as NOMAD to Eden Research. In line with its conflicts of interest policy, Shore Capital does not make formal recommendations on house stocks.
Carol

[northwick] 22/5/2017 22:48

Jaknife and PJ1

Sorry, I have to differ with both of you.

Remember, the company has already started shipping to France last Friday and this new source of revenue isn't factored in your figures (not sure how you got these in the first place). No one knows for sure what orders will come be from France and or other countries suffice to say it will far exceed last years shipment. See last years AGM presentation for more detail.

Time permitting, I will present my figures in detail over the next couple of days on which you all can comment, dissect or agree to. I am here to learn & educate myself from experienced shareholders.

[pj 1] 22/5/2017 22:20

Agree Jaknife. 10 years of previous failing history and yet some still believe.

Those who forget the past are condemned to repeat it.

[northwick] 22/5/2017 21:17

Think issues with Terpene Tech have now been put to bed beyond doubt with clearance from FRC amongst others such as HMRC. In addition, Eden's auditor's & Shore Capital would have long resigned and distanced themselves had there been any truth in any of the allegations. I have no concern with this aspect of Eden's business now.

However, there are other business related matters that requires more reading and research before I would add to my holding

[roydyor] 22/5/2017 21:15

From Tom five days ago.
"The WRN stooges on the BBs are perhaps unaware of my health issues...there are no crusades this summer"